DDInter1268 DDInter255
Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA reintroduced the drug to the market for multiple sclerosis. Natalizumab was further approved by the FDA for the treatment of Crohn's Disease in January 2008. On August 24, 2023, the first biosimilar to natalizumab, natalizumab-sztn, was approved by the FDA. Natalizumab was approved by the European Commission on September 22, 2023.
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Natalizumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Vitamin E {u} (Compound) binds {v} (Gene) GSTA2
GSTA2 {u} (Gene) is bound by {v} (Compound) Busulfan
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naltrexone
Naltrexone {u} (Compound) downregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Busulfan
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fludarabine
Fludarabine {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Busulfan
Natalizumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bedaquiline
Bedaquiline {u} (Compound) causes {v} (Side Effect) Arrhythmia
Arrhythmia {u} (Side Effect) is caused by {v} (Compound) Busulfan
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Busulfan
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fludarabine
Fludarabine {u} (Compound) binds {v} (Gene) DCK
DCK {u} (Gene) is downregulated by {v} (Compound) Busulfan
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Fingolimod {u} (Compound) causes {v} (Side Effect) Sinusitis
Sinusitis {u} (Side Effect) is caused by {v} (Compound) Busulfan
Natalizumab {u} may lead to a major life threatening interaction when taken with {v} Clofarabine
Clofarabine {u} (Compound) downregulates {v} (Gene) PSRC1
PSRC1 {u} (Gene) is upregulated by {v} (Compound) Busulfan
Natalizumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E (Compound) binds GSTA2 (Gene) and GSTA2 (Gene) is bound by Busulfan (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Busulfan (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Naltrexone and Naltrexone (Compound) downregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Busulfan (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Busulfan (Compound)
Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Bedaquiline and Bedaquiline (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Busulfan (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Busulfan (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fludarabine and Fludarabine (Compound) binds DCK (Gene) and DCK (Gene) is downregulated by Busulfan (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod (Compound) causes Sinusitis (Side Effect) and Sinusitis (Side Effect) is caused by Busulfan (Compound)
Natalizumab may lead to a major life threatening interaction when taken with Clofarabine and Clofarabine (Compound) downregulates PSRC1 (Gene) and PSRC1 (Gene) is upregulated by Busulfan (Compound)